title: Negligible role for NK cells and macrophages in delayed xenograft rejection.
abstract: Hyperacute rejection (HAR) of a discordant xenograft can be avoided by complement manipulation, but delayed xenograft rejection (DXR) still leads to graft loss. It is generally assumed that macrophages and NK cells play key roles in DXR. In the present study the survival times and cellular infiltrate following guinea pig to rat heart transplantation was analyzed in the course of DXR, following aspecific and specific manipulation of macrophages and NK cells. HAR was overcome by a single injection of cobra venom factor 1 day before heart transplantation. To aspecifically reduce the inflammatory response dominating DXR, dexamethasone (DEXA) was given. Treatment with DEXA markedly reduced infiltration by NK cells, macrophages, and granulocytes. It also led to prolonged graft survival times (median survival of 0.4 days, n = 10, P < 0.05). In the second series of experiments the specific roles of NK cells and macrophages in DXR were further assessed. Monoclonal antibody 3.2.3 was used to selectively deplete NK cells. Liposome-encapsulated dichloromethylene biphosphonate was given to achieve macrophage depletion. Neither of these specific treatments, alone or combined, led to prolonged graft survival. Immunohistology revealed that at day 2 after transplantation no NK cells or macrophages were present in grafts from the combined treatment group. Only a mild infiltration of granulocytes was observed. Collectively, these results strongly suggest that NK cells and macrophages are not likely to be pivotal cell types in DXR.
authors: Department of Surgery, Erasmus University Rotterdam, The Netherlands.
authors: K A
authors: KA
authors: van Overdam
authors: C A
authors: CA
authors: Verbakel
authors: E A
authors: EA
authors: Kouwenhoven
authors: N
authors: N
authors: van Rooijen
authors: R W
authors: RW
authors: de Bruin
authors: J N
authors: JN
authors: IJzermans
authors: R L
authors: RL
authors: Marquet
mesh_terms: D000818:Animals; D003169:Complement Inactivator Proteins / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004546:Elapid Venoms / Q000494:pharmacology; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006168:Guinea Pigs; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007694:Killer Cells, Natural / Q000276:immunology*; D008212:Lymphocyte Depletion; D008264:Macrophages / Q000276:immunology* / Q000473:pathology; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D014183:Transplantation, Heterologous / Q000276:immunology* / Q000473:pathology
chemical_list: D003169:Complement Inactivator Proteins; D004546:Elapid Venoms; C016310:cobra venom factor; D003907:Dexamethasone